MPM Oncology Impact Management »

Morphic Hldg shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Morphic Hldg (MORF) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Morphic Hldg

Tip: Access up to 7 years of quarterly data

All positions including Morphic Hldg held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Morphic Hldg by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $13M 369k 34.07
2024-03-31 $12M 325k 35.20
2023-09-30 $4.6M 200k 22.91

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Morphic Hldg

EcoR1 Capital
BlackRock
Vanguard Group
State Street Corporation
Goldman Sachs Group
Silverarc Capital Management
Two Sigma Advisers
MPM Oncology Impact Management
Fiduciary Trust Company
Candriam Luxembourg S.C.A.
Two Sigma Investments
Omega Fund Management
Morgan Stanley
Alliancebernstein
Nuveen Asset Management

View all funds holding Morphic Hldg